California Public Employees Retirement System Has $210,000 Position in Evolus Inc (EOLS)
California Public Employees Retirement System trimmed its holdings in shares of Evolus Inc (NASDAQ:EOLS) by 76.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,500 shares of the company’s stock after selling 25,000 shares during the quarter. California Public Employees Retirement System’s holdings in Evolus were worth $210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in Evolus during the 2nd quarter worth $108,000. Tower Research Capital LLC TRC lifted its position in Evolus by 761.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock worth $183,000 after acquiring an additional 5,794 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in Evolus during the 2nd quarter worth about $258,000. Alpine Woods Capital Investors LLC acquired a new stake in Evolus during the 2nd quarter worth about $280,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in Evolus during the 2nd quarter worth about $303,000. Hedge funds and other institutional investors own 24.40% of the company’s stock.
EOLS has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price target on shares of Evolus in a research report on Monday, September 17th. Zacks Investment Research cut Evolus from a “hold” rating to a “sell” rating in a research report on Tuesday, September 25th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $30.40.
Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Monday, November 5th. The company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.09). As a group, equities research analysts predict that Evolus Inc will post -1.84 EPS for the current fiscal year.
In related news, Director Kristine Romine acquired 6,347 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was acquired at an average price of $14.00 per share, with a total value of $88,858.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Corp Alphaeon sold 573,888 shares of the business’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $14.00, for a total value of $8,034,432.00. The disclosure for this sale can be found here.
COPYRIGHT VIOLATION NOTICE: “California Public Employees Retirement System Has $210,000 Position in Evolus Inc (EOLS)” was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.mareainformativa.com/news/2018/12/08/california-public-employees-retirement-system-sells-25000-shares-of-evolus-inc-eols-updated-updated-updated.html.
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Further Reading: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.